Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has an average analysts' rating of "Moderate Buy", with one sell and six buy ratings among the seven firms covering the stock.
• The average 12-month price target for Tenaya Therapeutics is $6.25, with analysts from HC Wainwright and Chardan Capital setting targets of $5.00 and $9.00 respectively.
• Institutional investors own 90.54% of Tenaya Therapeutics, highlighting significant confidence in the company's potential among hedge funds and investment firms.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $6.25.

Several equities analysts have weighed in on TNYA shares. HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of Tenaya Therapeutics in a research report on Tuesday, September 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Tenaya Therapeutics in a research report on Wednesday, October 8th. Chardan Capital reissued a "buy" rating and set a $9.00 price target on shares of Tenaya Therapeutics in a research report on Thursday, August 7th. Finally, Wall Street Zen raised Tenaya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th.

Institutional Investors Weigh In On Tenaya Therapeutics

Several hedge funds have recently made changes to their positions in TNYA. DAFNA Capital Management LLC acquired a new stake in shares of Tenaya Therapeutics during the first quarter worth $27,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Tenaya Therapeutics during the first quarter worth $33,000. Mirador Capital Partners LP boosted its holdings in shares of Tenaya Therapeutics by 38.2% during the third quarter. Mirador Capital Partners LP now owns 23,500 shares of the company's stock worth $38,000 after purchasing an additional 6,500 shares during the last quarter. CWM LLC boosted its holdings in shares of Tenaya Therapeutics by 14,231.7% during the first quarter. CWM LLC now owns 71,945 shares of the company's stock worth $41,000 after purchasing an additional 71,443 shares during the last quarter. Finally, Comerica Bank acquired a new stake in shares of Tenaya Therapeutics during the first quarter worth $50,000. Institutional investors and hedge funds own 90.54% of the company's stock.

Tenaya Therapeutics Price Performance

TNYA opened at $2.00 on Wednesday. The stock has a market cap of $325.95 million, a P/E ratio of -2.08 and a beta of 3.15. The stock's 50 day simple moving average is $1.31 and its 200 day simple moving average is $0.83. Tenaya Therapeutics has a 1-year low of $0.36 and a 1-year high of $4.01.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.06. Research analysts expect that Tenaya Therapeutics will post -1.35 EPS for the current fiscal year.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.